Iqbal Javeed, Amador Catalina, McKeithan Timothy W, Chan Wing C
Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, US.
Department of Pathology, City of Hope National Medical Center, Duarte, CA, USA.
Cancer Treat Res. 2019;176:31-68. doi: 10.1007/978-3-319-99716-2_2.
Peripheral T-cell lymphoma (PTCL) is an uncommon group of lymphoma covering a diverse spectrum of entities. Little was known regarding the molecular and genomic landscapes of these diseases until recently but the knowledge is still quite spotty with many rarer types of PTCL remain largely unexplored. In this chapter, the recent findings from gene expression profiling (GEP) studies, including profiling data on microRNA, where available, will be presented with emphasis on the implication on molecular diagnosis, prognostication, and the identification of new entities (PTCL-GATA3 and PTCL-TBX21) in the PTCL-NOS group. Recent studies using next-generation sequencing have unraveled the mutational landscape in a number of PTCL entities leading to a marked improvement in the understanding of their pathogenesis and biology. While many mutations are shared among PTCL entities, the frequency varies and certain mutations are quite unique to a specific entity. For example, TET2 is often mutated but this is particularly frequent (70-80%) in angioimmunoblastic T-cell lymphoma (AITL) and IDH2 R172 mutations appear to be unique for AITL. In general, chromatin modifiers and molecular components in the CD28/T-cell receptor signaling pathways are frequently mutated. The major findings will be summarized in this chapter correlating with GEP data and clinical features where appropriate. The mutational landscape of cutaneous T-cell lymphoma, specifically on mycosis fungoides and Sezary syndrome, will also be discussed.
外周T细胞淋巴瘤(PTCL)是一组少见的淋巴瘤,涵盖多种不同的实体类型。直到最近,人们对这些疾病的分子和基因组特征了解甚少,而且相关知识仍然很零散,许多较罕见类型的PTCL在很大程度上仍未得到充分研究。在本章中,将介绍基因表达谱(GEP)研究的最新发现,包括(如有)微小RNA的谱数据,重点是其对分子诊断、预后评估以及PTCL-NOS组中新实体(PTCL-GATA3和PTCL-TBX21)识别的意义。最近使用下一代测序的研究揭示了许多PTCL实体中的突变情况,这显著增进了我们对其发病机制和生物学特性的理解。虽然许多突变在PTCL实体中是共有的,但频率有所不同,某些突变在特定实体中相当独特。例如,TET2经常发生突变,但在血管免疫母细胞性T细胞淋巴瘤(AITL)中尤为常见(70-80%),而IDH2 R172突变似乎是AITL所特有的。一般来说,CD28/T细胞受体信号通路中的染色质修饰因子和分子成分经常发生突变。本章将总结主要发现,并在适当情况下与GEP数据和临床特征相关联。还将讨论皮肤T细胞淋巴瘤的突变情况,特别是蕈样肉芽肿和Sezary综合征的突变情况。